Abstract

A REVIEW ARTICLE ON DOSTARLIMAB

Aniket Haribhau Khatekar* and Reshma Shelke

.

Abstract

According to the World Health Organization, cancer will account for about 10 million fatalities in 2020, or nearly one in every six deaths, making it the leading cause of death worldwide (WHO). The most common cancers in 2020 will be prostate (1.93 million cases), colon and rectum (1.93 million cases), lung (2.21 million cases), breast (2.26 million cases), and lung (2.21 million cases) (1.41 million Cases). In 2020, there will be 19 million cancer cases recorded worldwide, with colorectal cancer (CRC) accounting for 10% of cases and 9.4% of deaths. There is a severe dearth of cancer treatment facilities in developing nations like Pakistan, where there is a high prevalence of CRC. The five CCR treatment medications that have received FDA approval (Durvalumab, Atezolizumab, Nivolumab, Pembrolizumab, and Avelumab) have a significant incidence of grade 3–4 negative side effects. Dostarlimab is a humanised monoclonal antibody that binds to PD-1 with a high affinity, inhibiting the binding of PD-L1 and PD-L2 molecules. We provide preliminary data from endometrial cancer (EC) patients taking part in a phase I study of the single drug dostarlimab.

Keywords: Dostarlimab; Immunotherapy; cancer, anti-PD-1 antibody; Dostarlimab.